Results 251 to 260 of about 21,604,258 (289)
Some of the next articles are maybe not open access.

Chimeric antigen receptor T-cell therapy for melanoma

Expert Review of Clinical Immunology, 2021
In recent years, chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment. After initial therapeutic success for hematologic malignancies, this approach has been extended for the treatment of solid tumors including melanoma.T cells need to be reprogramed to recognize specific antigens expressed only in tumor cells, a difficult ...
Azadehsadat Razavi   +3 more
openaire   +2 more sources

Chimeric antigen receptor T‐cell therapy toxicities

British Journal of Clinical Pharmacology, 2020
Cancer immunotherapy has greatly advanced in recent years, with chimeric antigen receptor (CAR) T cells emerging as an innovative technology that harnesses the immune system to fight malignant diseases. These genetically engineered T‐cells have shown encouraging results for B‐cell lymphoid malignancies and are now being explored for other cancer types.
Uri Greenbaum   +7 more
openaire   +2 more sources

The Future of Chimeric Antigen Receptor T Cell Therapy

Hematology/Oncology Clinics of North America, 2023
Over the last 10 years CAR T cell therapies have been shown to be transformative for B- and plasma-cell malignancies, however the field is only beginning to realize the potential benefit to patients of such therapies. Over the next 10 years it is expected that advances will be made in durable response rates for patients with B/plasma cell malignancies;
openaire   +2 more sources

Chimeric antigen receptor T-cell therapy for glioblastoma

Translational Research, 2017
Chimeric antigen receptor (CAR) T-cell therapy has shown great promise in the treatment of hematological disease, and its utility for treatment of solid tumors is beginning to unfold. Glioblastoma continues to portend a grim prognosis and immunotherapeutic approaches are being explored as a potential treatment strategy.
Analiz Rodriguez   +2 more
openaire   +2 more sources

Chimeric antigen receptor T-cell therapies for lymphoma

Nature Reviews Clinical Oncology, 2017
New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and relapse after autologous stem-cell transplantation are indicators of an especially poor prognosis.
Jennifer N, Brudno   +1 more
openaire   +2 more sources

Chimeric Antigen Receptors for T-Cell Based Therapy

2012
The Chimeric Antigen Receptor (CAR) consists of an antibody-derived targeting domain fused with T-cell signaling domains that, when expressed by a T-cell, endows the T-cell with antigen specificity determined by the targeting domain of the CAR. CARs can potentially redirect the effector functions of a T-cell towards any protein and nonprotein target ...
Cheadle, Eleanor   +11 more
openaire   +5 more sources

Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma

NeuroMolecular Medicine, 2021
Glioblastoma (GBM) are the most common and aggressive primary brain tumors in adults. Current mainstay treatments include surgery, chemotherapy, and radiation; however, these are ineffective. As a result, immunotherapy treatment strategies are being developed to harness the body's natural defense mechanisms against gliomas.
Lisa Feldman   +2 more
openaire   +2 more sources

Chimeric antigen receptor T cells therapy in solid tumors

Clinical and Translational Oncology, 2023
Chimeric antigen receptor T cells therapy (CAR-T therapy) is a class of ACT therapy. Chimeric antigen receptor (CAR) is an engineered synthetic receptor of CAR-T, which give T cells the ability to recognize tumor antigens in a human leukocyte antigen-independent (HLA-independent) manner and enables them to recognize more extensive target antigens than ...
Fatimah Rababah   +9 more
openaire   +2 more sources

Complications of Chimeric Antigen Receptor T-cell Therapy

Emergency Medicine Clinics of North America
Chimeric antigen receptor T-cell therapy is a modern approach in our treatment of cancer. However, it is not without potential side effects. While cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are some of the more well-known toxicities, other potential complications include B- and T-cell aplasia ...
Gregory, Chang, Brian, Cameron
openaire   +2 more sources

Home - About - Disclaimer - Privacy